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Abstract
Background: Systemic Lupus Erythematosus (lupus) is a chronic autoimmune disease that can impact any organ
system and result in life-threatening complications. African-Americans are at increased risk for morbidity and
mortality from lupus. Self-management programs have demonstrated significant improvements in health distress,
self-reported global health, and activity limitation among people with lupus. Despite benefits, arthritis self-
management education has reached only a limited number of people. Self-selection of program could improve
such trends. The aim of the current study is to test a novel intervention to improve quality of life, decrease
indicators of depression, and reduce perceived and biological indicators of stress in African-American lupus patients
in South Carolina.
Methods/Design: In a three armed randomized, wait list controlled trial, we will evaluate the effectiveness of a
patient-centered ‘a–la-carte’ approach that offers subjects a variety of modes of interaction from which they can
choose as many or few as they wish, compared to a ‘set menu’ approach and usual care. This unique ‘a-la-carte’
self-management program will be offered to 50 African-American lupus patients participating in a longitudinal
observational web-based SLE Database at the Medical University of South Carolina. Each individualized intervention
plan will include 1–4 options, including a mail-delivered arthritis kit, addition and access to an online message
board, participation in a support group, and enrollment in a local self-management program. A ‘set menu’ control
group of 50 lupus patients will be offered a standardized chronic disease self-management program only, and a
control group of 50 lupus patients will receive usual care. Outcomes will include changes in (a) health behaviors,
(b) health status, (c) health care utilization, and (d) biological markers (urinary catecholamines).
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Discussion: Such a culturally sensitive educational intervention which includes self-selection of program components
has the potential to improve disparate trends in quality of life, disease activity, depression, and stress among African-
American lupus patients, as better outcomes have been documented when participants are able to choose/dictate the
content and/or pace of the respective treatment/intervention program. Since there is currently no “gold standard” self-
management program specifically for lupus, this project may have a considerable impact on future research and policy
decisions.
Trial registration: NCT01837875; April 18, 2013
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Background
Lupus disease experience of African Americans
Systemic Lupus Erythematosus (SLE) is a chronic auto-
immune disease with acute periodic flare-ups of symp-
toms impacting any organ system and resulting in
potentially life-threatening complications [1, 2]. SLE dis-
proportionately affects nonwhites [3], and a number of
studies have shown that African-Americans are at in-
creased risk for morbidity and mortality from SLE [4–9].
In these studies, SLE occurrence was three to four times
higher among African-American than Caucasian white
women, and high levels of disease activity are more
commonly observed in African-Americans [8–10]. Other
significant complications of treatment include weight
gain, osteoporosis, osteonecrosis, accelerated athero-
sclerosis, and retinal damage [1, 2, 11, 12]. These side ef-
fects and complications can lead to significant functional
and emotional challenges. Patients often experience a
high degree of psychological symptoms, including anx-
iety, depression, mood disorders, and decreased health-
related quality of life [13–18]. In addition to managing
disease-specific stressors, it has been suggested that
African-Americans are exposed to a unique set of risk
factors that lead to a pattern of cumulative disadvantage
over time. High rates of unemployment, poverty, violent
crime, incarceration, and homicide among African-
American adults reflect this accumulation of disadvan-
tage at multiple transition points during their develop-
ment and across the life course [19–31]. It is highly
likely that early childhood exposure to segregated, eco-
nomically impoverished neighborhoods created by insti-
tutionalized racism adversely affects child health and
growth and sets the Black child on a low education and
economic trajectory that increases the risk of poor phys-
ical and mental health in adulthood [22]. Additional
stressors include deprivation of resources and facilities,
differential exposure to health risks in the physical envir-
onment because of economically disadvantaged neigh-
borhoods and poor quality housing, higher costs of
goods and services in deprived areas, as well as roles of
social networks and social capital, which often give rise
to peer pressure against academic achievement and in
support of crime and substance use [19, 20, 23, 24]. Due
to the exposure of African-Americans to a unique trajec-
tory of stressors throughout the life course, it may be
critical to address modifiable risk factors for SLE that
may be further exacerbated by this trend in an effort to
improve health status and reduce health disparities in
this high risk group.
Evidence based prevention programs
A large body of evidence has shown that health-
promoting programs in stress management have been
successful in helping people improve their health prac-
tices and related health conditions [25]. Based on re-
views of scientific literature, investigators have suggested
that therapeutic interventions should be proposed to re-
duce psychological distress to improve quality of life and
possibly moderate the evolution of chronic and unpre-
dictable diseases like SLE [32]. Cognitive-behavioral
stress management (CBSM) techniques have resulted in
short-term improvement in pain, psychological function,
and perceived physical function among persons with
SLE [27]. Additionally, psychoeducation [33] and graded
aerobic exercise [34] have been shown to be useful in
the management of fatigue. Programs designed to reduce
stress levels of chronically ill patients have also included
support therapy, lifestyle interventions incorporating ele-
ments of yoga or other similar disciplines, and mini-
sessions on depression, adaptive coping strategies, and
body image [27–29]. Although there is no generally ac-
cepted self-management program available for SLE [16],
two programs that have been shown to be successful in
improving conditions in patients with arthritis are the
Arthritis Self- Management Program (ASMP) and the gen-
eric Chronic Disease Self-Management Program (CDSMP).
Each program incorporates six weeks of peer led sessions
ranging in disease-specific and more general self-help con-
tent. Arthritis self-management education delivered by
small-group, home study, computer, and Internet modal-
ities have demonstrated significant improvements in health
distress, self-reported global health, and activity limitation,
with trends toward improvement in self efficacy and men-
tal stress management [31, 35–57].
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Barriers to participation
Despite the apparent need for help with multiple illness-
related problems and evidence that some of these
problems can be ameliorated with cognitive-behavioral
interventions without adverse effect, several studies have
emphasized the need to design interventions that ad-
dress barriers to participation and curtail noncompliance
[58–61], particularly for African-American patients.
Practicing physicians continue to struggle with patient
compliance, poor adherence to therapeutic regimens,
and failure of patients to keep scheduled appointments.
For example, Petri et al. (1991) found that physicians
rated African-Americans as less globally adherent than
whites (43.5 % versus 66.3 % adherent, respectively) [62].
Despite recommendations from numerous national
agencies that self-management education complement
medical care [25, 43–47], arthritis self-management edu-
cation has reached a limited number of people. Many
Arthritis Foundation chapters have had difficulty dissem-
inating arthritis self-management education programs.
Additionally, many vulnerable populations have not been
included in study samples [40, 42, 45, 51, 63–66]. Compli-
ance is also a persistent problem in standardized pro-
grams. One study reported that less than 50 % of a closed
eligible population participated, even when Internet and
small-group programs were offered repeatedly over many
years [67], suggesting that interventions may not be reach-
ing the largest portion of lupus cases. Self-selection of pro-
gram components has not been explored as an approach
to improve such trends, but better self-management out-
comes have been documented when participants are able
to choose/dictate the content and/or pace of the respect-
ive treatment/intervention program [68–71].
Study aims
The overall hypothesis of this proposal is that a cultur-
ally sensitive educational intervention which includes
self-selection of program components will lead to im-
proved quality of life and health status among African-
American patients with lupus. Our specific aims are:
1) To provide an intervention that employs a patient-
tailored approach and offers a variety of modes of
interaction from which patients can choose; 2) Measuring
efficacy, implementation, and adoption/maintenance,
using the Reach, Effectiveness, Adoption, Implementation,
and Maintenance (RE-AIM) framework, which offers a
comprehensive approach to considering five dimensions
important for evaluating the potential public health im-
pact of an intervention [72–79]; and 3) To use previously
collected data to characterize patient-centric barriers to
care in African-American lupus patients.
Our approach maximizes chances of success in im-
proving quality of life, decreasing indicators of disease
activity and depression, and reducing perceived and
biological indicators of stress among African-American
lupus patients. In an effort to circumvent barriers to par-
ticipation and approach this problem in a real-world
fashion, we will incorporate the documented needs and
desires of the target population into the design. In
addition to filling a critical gap in steps to validate vari-
ous hypothesized mechanisms in lupus, particularly in
African Americans, who are at highest risk for the dis-
ease, such a preliminary investigation may demonstrate
that this method effectively reduces perceived and bio-
logical indicators of stress and should be considered as
an adjunct to standard medical care for this high risk
group. Intervention program components will be largely
adapted from the work and guidance of Dr. Kate Lorig,
original creator of the internationally-adopted Arthritis
Self-Management Program and a mentor on this pro-
posal. Indicators of stress, depression, and quality of life
will be evaluated among a cohort of African-American
lupus patients participating in an ongoing SLE Clinic
Database Project at the Medical University of South
Carolina (MUSC). The availability of uniform data de-
tailing the sociodemographic and disease profile char-
acteristics of SLE Clinic Database participants and
overarching RE-AIM framework will allow for the in-
vestigation of differences in those who choose not to
participate, respond, or adopt program components.
Methods/Design
Study design
SPIRIT guidelines have been adhered to for the reporting
of this protocol. As depicted in Fig. 1, IQAN is a three
armed randomized, wait list controlled trial to compare
a patient-centered ‘a–la-carte’ approach that offers sub-
jects a variety of modes of interaction from which they
can choose as many or few as they wish (IQAN inter-
vention) to a ‘set menu’ approach. A unique ‘a-la-carte’
self-management program will be offered to 50 African-
American lupus patients participating in an ongoing SLE
Clinic Database Project at MUSC. A ‘set menu’ control
group of 50 lupus patients will be offered a standardized
chronic disease self-management program only, and a
control group of 50 lupus patients will receive usual care
(UC), void of intervention components. The intervention
will be coordinated by an Intervention Coordinator, with
assistance from local/MUSC Study Coordinators. The
Intervention Coordinator will work with each participant
in the intervention arm to create an individualized inter-
vention plan (IIP). Each IIP will include 1–4 options, in-
cluding a mail-delivered arthritis kit, addition and access
to a listserv, participation in a support group, and enroll-
ment in local self-management program(s). Due to the
nature of the IIP, the proposed intervention will inher-
ently vary by participant. To ensure intervention integ-
rity, discrete components will follow written protocols
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and peer leaders will complete a standardized checklist
for each session/encounter. The total number of study
visits will depend on group assignment and intervention
participation. The entire study is over a period of 2 years.
Location will vary depending upon the randomly
assigned intervention. Locations range from a home set-
ting to a set community meeting location. We expect
the proposed study to demonstrate that a unique inter-
vention strategy can reduce disease activity and damage,
as well as perceived and biological indicators of stress,
Fig. 1 Study design
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while improving quality of life indicators in African-
American lupus patients. Measures of psychosocial and
neuroendocrine responses to stress and disease activity
and damage indices are expected to be inversely related
to participation in intervention activities. Indicators of
quality of life are expected to be positively related to par-
ticipation. Validated measures of stress, depression, and
quality of life will be collected in all patients in each
condition before and after intervention activities.
Study setting and patients
The total number of individual patients with SLE cur-
rently being followed by clinicians at MUSC is 1,121
within the past 3 years. The total number of new pa-
tients with SLE seen in the past year by clinicians at
MUSC was 176, of which 61 % were African-American
and 88 % were female. Patients invited to participate in
the proposed study are African-American lupus patients
participating in a longitudinal observational web-based
SLE Database at MUSC. There are 402 patients with
lupus currently enrolled, and these patients are seen on
a regular basis in the MUSC lupus clinics. All patients
have American College of Rheumatology (ACR) criteria
and disease activity information available, as well as
quality of life measures obtained in the database ques-
tionnaire. All SLE patients met at least four components
of the 1997 ACR revised criteria for SLE [80]. The vast
majority of subjects have had serum/urine/DNA/RNA
specimens collected, stored, and shared with collabora-
tors across the U.S, resulting in many important discov-
eries in the genetics and epidemiology of lupus. The
database is web-based, allowing quick identification of
potential participants in clinical trials since, as part of
the informed consent process, participants agree to fu-
ture re-contact regarding other research studies. Of the
402 patients with lupus, 336 are African-American, and
218 of the 336 are Gullah African-American from the
Sea Islands of South Carolina and Georgia. Additionally,
as part of the associated SLE in Gullah Health
(SLEIGH), 166 unrelated age- and gender-matched
Gullah controls and 216 family-member Gullah controls
are enrolled.
Target enrollment for the study is 150 patients who
meet the following study eligibility criteria: a) have been
diagnosed with lupus; b) be at least 18 years of age; c) free
of central nervous system (CNS)/neuropsychiatric lupus
and dementia; and d) not be a participant in the ASMP or
CDSMP. Patients are excluded if they: a) are younger than
18 years of age; b) are not African American; c) do not
have a confirmed diagnosis of lupus; d) have been di-
agnosed with CNS/neuropsychiatric lupus and demen-
tia; and/or e) have been or are currently a participant





Recruitment will be achieved on a systematic, random-
ized basis to be able to characterize respondents vs.
non-respondents and more effectively document Reach
or the percent and representativeness of individuals will-
ing to participate. Three waves of recruitment will be
implemented, each targeting up to 112 of the 336
African-American lupus patients currently enrolled in
the MUSC SLE Database who have agreed to future con-
tact. Recruitment efforts will be limited to participants
residing in areas where self-management programs are
offered who are free of CNS/neuropsychiatric lupus and
dementia. Each wave will be one month in duration and
include an initial mailed postcard describing the project
and distribution of flyers with the same information dur-
ing MUSC lupus clinic visits, both inviting interested pa-
tients to learn more about the proposed study, meet the
investigative team, enroll in the study, and complete
consent documents.
Randomization
Within a month of all signed informed consent forms and
baseline assessments being returned, the Biostatistician or
their graduate assistant (GA) will enter baseline data and
randomly assign each participant to one of three study
arms: (1) intervention, (2) set menu control, or (3) control,
returning that information to the principal investigator
(PI) and Intervention Coordinator. Randomization will be
stratified according to level of education (i.e., high school
diploma or greater vs no diploma), or employment
(more than 30 h per week vs less than 30 h), or in-
come (SSI vs ≤ 25,000 vs > 25,000), depending on the
completeness of data provided by the MUSC Study
Coordinator. Within a month of randomization, the
Intervention Coordinator will contact 50 intervention
arm participants and assess and record their interven-
tion modes of choice. The intervention coordinator
will provide URL for listserv, support group details,
and coordinate mailing of arthritis kits as applicable.
The Intervention Coordinator will then link interested
intervention arm and all set menu control arm partici-
pants to CDSMP’s in their area. The GA will make cour-
tesy calls to the 50 participants in the control group
letting them know of their designation and when they can
expect contact and next round of evaluation materials to
be completed and returned for compensation.
Description of the intervention
The intervention will be coordinated by an Intervention
Coordinator, with assistance from local/MUSC Study
Coordinators. The Intervention Coordinator will work
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with each participant in the intervention arm to create
an IIP. Each IIP will include 1–4 options, including a
mail-delivered arthritis kit, addition and access to a list-
serv, participation in a support group, and enrollment in
local self-management program(s). Due to the nature of
the IIP, the proposed intervention will inherently vary by
participant. The total number of study visits will depend
on group assignment and intervention participation. The
entire study is over a period of 2 years. Location will
vary depending upon the randomly assigned interven-
tion. Locations range from a home setting to a set com-
munity meeting location.
For the past 5 years, South Carolina has been moving
toward statewide infrastructure development for evidence
based prevention programs (EBPPs). Under the combined
leadership of the South Carolina Department of Health
and Environmental Control (SCDHEC) and the South
Carolina Lieutenant Governor’s Office Administration
(SCLGOA), a number of EBPPs have been integrated into
the program delivery of many aging services organizations
and other local partner organizations. The Intervention
Coordinator will assist interested participants with enroll-
ment, and participants will be encouraged to take advan-
tage of other programs after study completion.
Arthritis Foundation Self-Help Program
The Arthritis Foundation Self-Help Program (AFSHP)
was the first patient education program developed by
Stanford University. It is a 2-h workshop given weekly
for six weeks in a variety of community settings, such as
senior centers, churches, libraries, and hospitals. People
with different types of rheumatic diseases, such as osteo-
arthritis, rheumatoid arthritis, fibromyalgia, lupus, and
others, attend in a group format. Workshops are fa-
cilitated by two trained leaders, one or both of whom
are non-health professionals with arthritis. Topics
covered include: 1) techniques to deal with problems
such as pain, fatigue, frustration and isolation, 2) ap-
propriate exercise for maintaining and improving
strength, flexibility, and endurance, 3) appropriate use
of medications, 4) communicating effectively with
family, friends, and health professionals, 5) healthy eating,
6) making informed treatment decisions, 7) disease related
problem solving, and 8) getting a good night's sleep. It is
the process in which the program is taught that makes it
effective. Classes are highly interactive and engaging,
where mutual support and success build the patients’
confidence in their ability to manage their health and
maintain active and fulfilling lives.
Chronic disease self-management – better choices better
health
The Chronic Disease Self-Management Program (CDSMP)
is a 2.5 h workshop given weekly for six weeks. Like the
Arthritis Foundation Self-Help Program, it was developed
by Stanford University and is also offered in a variety
of community settings (e.g., senior centers, churches,
hospitals). People with different chronic health prob-
lems attend together and support one another in
making positive changes in their health. Workshops
are facilitated by two trained leaders, one or both of
whom are non-health professionals with a chronic disease
themselves. Subjects covered include: 1) techniques to
deal with problems such as frustration, fatigue, pain and
isolation, 2) appropriate exercise for maintaining and im-
proving strength, flexibility, and endurance, 3) appropriate
use of medications, 4) communicating effectively with
family, friends, and health professionals, 5) nutrition, and,
6) how to evaluate new treatments. It is the process in
which the program is taught that makes it effective.
Classes are highly participative, and mutual support builds
the participants’ confidence in their ability to manage their
health and maintain active and fulfilling lives. The
CDSMP is the fastest growing EBPP in South Carolina.
The Intervention Coordinator will also assist participants
in the set menu control arm with enrollment in this
program.
Mail-delivered arthritis kit
The Arthritis Self-Management Tool Kit is packaged in
a plastic envelope and contains 1) a “Self-Test” to
help participants determine how arthritis affects their
lives and self-tailor the use of the Tool Kit, including
items related to pain, fatigue, physical limitations,
and health worries; participants score this test them-
selves and are directed to specific parts of the Tool
Kit based on their scores; 2) information sheets:
Working with Your Doctor and the Health Care System;
Exercise; Medications; Healthy Eating; Fatigue and Pain
Management; Finding Community Resources; and Dealing
with One’s Emotions; 3) information sheets on key process
components of the ASMP: Action Planning, Problem
Solving, Deciding What to Try, and Individualizing an
Exercise Program; 4) The Arthritis Helpbook [81]; 5) audio
relaxation and exercise compact discs (CDs); and 6) an
audio CD of all material printed on the information
sheets.
Support group
Interested participants will be referred to the “Lupus:
Listening and Learning Group”, a Charleston-based sup-
port group affiliated with the Lupus Foundation of
America (LFA). One to two LFA-trained facilitators im-
plement the group. Notices are placed in community pa-
pers, radio stations, and public access events calendars,
as well as rheumatology offices and in emerging social
networking modalities like Facebook. Additional out-
reach activities, such as presence at community health
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fairs, communication with local churches and network-
ing with community-based organizations, would be
welcomed in order to invite additional support group
participants. The meeting format generally includes a
specific discussion topic or an informative presentation
such as by a medical or counseling professional, pharma-
cist, or lupus researcher. This program is followed by
time within the group for further interaction and sup-
port among the attendees who wish to participate. The
Lupus: Listening and Learning Group is open to all
lupus patients, family members, friends and supporters,
and there is no pre-registration or fee involved.
Listserv
A project listserv will be established to link all interven-
tion participants to facilitate exchange of coping strat-
egies, pose questions, and share preferred educational
resources or any other information relative to their
everyday and disease-specific experiences and/or partici-
pation in the project. Participants will be provided with
a URL, from which they will be able to subscribe to the
listserv. Once subscribed, they will be able to post and
receive messages, managed by a listserv moderator, who
will be responsible for distribution to listserv members
as appropriate. Participants will have the option to un-
subscribe at any time.
Handling of study interventions
To ensure intervention integrity, discrete components
will follow written protocols and peer leaders will
complete a standardized checklist for each session/
encounter. Each IIP will be reviewed on a quarterly
basis (every 3 months), at which time measures will be
repeated and the participant will be invited to change
and/or add options to their plan.
Concomitant interventions
During the first intervention year, intervention arm par-
ticipants will have the option of participating in a mail-
delivered arthritis kit, addition and access to a listserv,
participation in a support group, and/or enrollment in
local self-management program(s). After one year, set
menu controls and controls will be invited to participate
in the same options that were originally extended to
intervention participants. During the first intervention
year, set menu control arm participants will not have the
option of participating in a mail-delivered arthritis kit,
addition and access to a listserv, or participation in a
support group. Control arm participants will not have
the option of participating in any of the four offered
intervention modalities. None of the offered intervention
modes are required.
Adherence assessment
In addition to quarterly review of their IIP, intervention
participants will receive biweekly follow up calls to gauge
their progress, comfort, adherence, and occurrence of any
adverse events. In addition to enrollment in a local
CDSMP, participants in the set menu control arm will re-
ceive monthly follow up calls to gauge their progress,
comfort, adherence, and occurrence of any adverse events.
Set menu controls will complete post-intervention
follow-up evaluations bi-annually. Participants in the
control arm will not receive follow-up calls, but will
complete post-intervention follow-up evaluations on
the same schedule as set menu controls. At their sec-
ond post-intervention follow-up evaluation (after one
year), set menu controls and controls will be invited
to participate in the intervention activities of the pro-
gram and have the opportunity to create their own
IIP with the same options that were originally ex-
tended to intervention participants. From then, all
participants will review their plan with the interven-
tion coordinator on a quarterly basis, at which time
measures will be repeated and each participant will
be invited to change and/or add options to their plan.
All participants will then receive monthly follow up
calls to gauge their progress, comfort, adherence, and
occurrence of any adverse events.
Outcomes assessments
Study assessments will be completed at baseline,
6 months, 12 months, 18 months, with a final evaluation
at 24 months, for a total of five assessments. All patients
who have agreed to participate will be mailed question-
naires for completion and compensation upon return,
along with return postage and instructions for com-
pleting instruments. A randomly selected sub-sample
(n = 50) of interested patients will be invited for as-
sessment of urine catecholamine levels and urine collec-
tion instructions will be included in their mailed materials
at baseline and 24 months/final evaluation. Mailed assess-
ments will include: The Arthritis Self-Efficacy Scale, the
Personal Health Questionnaire Depression Scale (PHQ-9),
the Lupus Quality of Life Questionnaire (LUP-QOL),
the Systemic Lupus Activity Questionnaire (SLAQ),
and the Stanford Patient Education Research Center
Questionnaires assessing medical outcomes such as hos-
pital visits, illness intrusiveness, and use of stress manage-
ment techniques.
Primary outcome
We expect the proposed study to demonstrate that a
unique intervention strategy can reduce disease activity
and damage, as well as perceived and biological indica-
tors of stress, while improving quality of life indicators
in African-American lupus patients. This will result in
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changes (a) health behaviors (use of stress management
techniques), (b) health status (quality of life, depression,
perceived psychosocial stress, and disease activity), (c)
health care utilization (hospitalizations, emergency room
visits, and communication with physicians) and (d) bio-
logical markers (urinary catecholamines).
Secondary outcome
Measures of psychosocial and neuroendocrine responses
to stress and disease activity and damage indices are
expected to be inversely related to participation in inter-
vention activities. Indicators of quality of life are ex-
pected to be positively related to participation.
Self-report measures
Standardized methods will be employed for measuring
associated outcomes in a validated fashion. Multiple
measures were chosen to assess the impact of the inter-
vention on targeted outcomes and quality of life. The
criteria for choosing instruments and techniques were
that they have been previously validated (preferably in
African American populations), represent key outcomes
in one or more past studies of chronic conditions
(preferably lupus), are relatively brief (no more than 50–
60 questions total), and sensitive to change in the range
of 0.2 effect size. Selected measurement instruments are
described below. Depending on participant preference,
questionnaires will be mailed (paper and electronic) or
administered by telephone. All biological samples for
analysis will be promptly processed in a Labcorp facility
to ensure standardization of assessment.
Psychosocial stress
Psychosocial stress will be assessed by the Arthritis Self-
Efficacy Scale pain and other symptoms sub-scale [82],
which consists of 11 items designed to measure confi-
dence in one’s ability to manage the pain, fatigue, frus-
tration, and other aspects of disease; it was reworded in
previous investigations to reflect lupus rather than
arthritis [39].
Depression
Depression will be assessed by the PHQ-9 adapted by
the Stanford Patient Education Research Center [83, 84].
The nine-item scale assesses the presence and frequency
of depressive symptoms over the past two weeks, yield-
ing a score range of 0–27 where a score of 15 or greater
is considered major depression, and 20 or more is severe
major depression.
Quality of life
Quality of life will be assessed using two instruments
that describe a spectrum of quality of life outcomes. The
LUP-QOL incorporates the Medical Outcomes Study
(MOS) Short Form 36 Health Survey (SF-36) and the
Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F), which are reliable and valid instru-
ments that are frequently used in quality of life studies
of persons with lupus [85–87]. The questionnaire in-
cludes questions pertaining to physical function, role
function, social function, mental health, health percep-
tion and pain.
Neuroendocrine response to stress
Assessment of urinary catecholamine levels will require
that the identified sub-sample of participants collect
their own samples in a brown 24-h urine container with
30 mL 6 N hydrogen chloride (HCl) of urine collected
and the date/time collection started and finished. Sam-
ples will need to be kept refrigerated between collections
and then the completed container kept on ice until cou-
riers pick up samples and bring them back to the lab for
testing. Random subjects will be asked for an immediate
additional collection to assess variability imposed by
participant-specific factors. A 4–30 mL aliquot is neces-
sary for analysis. Assessment of urinary catecholamines
includes tests of urinary epinephrine, norepinephrine,
and dopamine, which will be quantified using liquid
chromatography/tandem mass spectrometry (LC/MS-MS)
[88–90]. Once results are complete, they will be sent via
Autofax.
Disease indices
Possible disease activity will be assessed using SLAQ
[91]. The Systemic Lupus Activity Measure (SLAM) is a
physician-rated, 31-item instrument that assesses symp-
toms and objective findings in the month prior to evalu-
ation, in nine organ systems and seven laboratory items
[92, 93]. Individual items are rated on a scale from 0 to
3 based on severity and are scored positively only if dir-
ectly attributable to SLE. The SLAQ is based on items
from the SLAM that could be self-reported. It asks a
single Patient Global Assessment (PGA) question about
presence and severity of lupus activity over the past
month, questions on 24 specific symptoms of disease ac-
tivity including weight loss, fatigue, fevers, oral ulcers,
malar rash, photosensitivity, vasculitis, other rashes, alo-
pecia, lymphadenopathy, dyspnea, chest pain, Raynaud’s
phenomenon, abdominal pain, paresthesia, seizures,
stroke, memory loss, depression, headaches, myalgias,
muscle weakness, arthralgias, and joint swelling, and a
single Numerical Rating Scale (NRS) asking the patient
to rate disease activity on a scale of 0–10 over the past
three months with the 0 anchored by ‘no activity’ and 10
anchored by ‘most activity’. The patient is then asked to
rate the most active day over the past three months.
Likert responses with four response categories (no
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problem, mild, moderate, severe) are used for the PGA
and specific symptom questions.
To assess use of prednisone, immunosuppressive
agents, nonsteroidal anti-inflammatory drugs [NSAIDs],
and/or hydroxychloroquine), participants will also be
asked to provide a listing of concomitant medications they
are taking, to include the name of the medication, dose,
unit, frequency, route, start date, stop date, and whether
the medication will be ongoing at the end of the study. To
account for factors that may affect catecholamine observa-
tions, participants will also be asked to include alcohol,
caffeine, illegal/street drugs, and alternative remedies.
Behavior change
Stanford Patient Education Research Center Question-
naires assessing medical outcomes such as hospital
visits, illness intrusiveness, and use of stress manage-
ment techniques [70, 77–79] will be used to further as-
sess adoption and maintenance. These are behavior
change scales, modified from the Medical Outcomes
Study, to determine if participants are practicing cogni-
tive stress reduction (pain reduction) and non-cognitive
(mental stress management/ relaxation) techniques.
These scales also assess whether key behaviors concern-
ing communicating with health care providers and
health care utilization have changed. Additionally, par-
ticipants will have the opportunity to rate the credibility
of the intervention and their expectancy of improve-
ment. Participants will also be asked to keep diaries of
practice during the intervention period. The number of
diaries returned and self-ratings of practice frequency
will be used to estimate adherence to intervention tech-
niques and practices.
Sample size and power
There will be three study arms in the proposed study;
(1) intervention, (2) set menu control, and (3) control.
Due to the potential similarity in each arm, a cluster-
random trial will be considered, which takes into ac-
count between-cluster variation [94]. Relevant interven-
tion literature shows effect sizes varying from 30-80 %
[26, 29, 31, 39, 42, 45, 46, 49–51], which will be ad-
equate for the proposed sample size design. The study
will evaluate the difference in disease indices, quality of
life and perceived and biological indicators of stress be-
tween the intervention and control groups, as well as
within each group according to individual levels of inter-
vention participation. Therefore, estimated sample sizes
are displayed in Table 1 under a variety of effect sizes
and drop-out levels in order to obtain a 0.95 significance
level and 0.8 power of study. Our target recruitment level
will be 150 participants according to an 80 % power level,
in an effort to capture smaller effect sizes. This will corres-
pond to an approximate 45 % response rate (N = 336),
which is well within response and participation in other
studies among the MUSC lupus cohort. Based on these re-
sults there is good to adequate power for most analyses to
make the proposed project feasible.
Data analytic plan
Quantitative data analysis
Data will be entered immediately after specified collec-
tion points into an Excel worksheet that will be built
upon after each collection point and imported into SAS
for data manipulation. To minimize risks to confidential-
ity, all data will be de-identified by assigning a numeric
code to each participant and labeling all materials corre-
sponding to that participant with their unique identifier.
Additionally, data files that include personal identifiers
will be stored separately from signed consent forms in
locked file cabinets that only the Principal Investigator
will have access to. The basic experimental design and
corresponding data analyses will represent a one-
between subjects (intervention versus control and inter-
vention versus set menu control) and one-within or re-
peated factor (pre, post, and follow up assessments)
crossed factorial design, with multiple dependent out-
come measures (disease activity and damage, perceived
and biological indicators of stress, quality of life, and
urine catecholamines). The multivariate (multiple quali-
tatively distinct measures at multiple times) approaches
to repeated measures [95, 96], based on the general lin-
ear model or general linear mixed model, will be used to
test for pre-post-follow up changes between the inter-
vention group and the control groups, as well as for ex-
ploratory correlations with urine catecholamines. These
approaches provide better description of longitudinal
patterns for each dependent variable and they are easier
to successfully implement and generally more powerful
than the use of covariant models when multiple
outcome measures are considered simultaneously [96].
P < 0.05 will be used to indicate statistical significance.
The data from all randomized participants will be ana-
lyzed. Multiple imputations will be used to estimate
missing data from dropouts and those participants who
do not complete follow up evaluations. We will evaluate
the first 12 months to address primary outcomes and ex-
ploratory analyses will be conducted after 12 months
once participants are given the option to cross over.
Basic descriptive statistics such as means, ranges, and
Table 1 Estimated sample size calculations
Estimated sample sizes
Effect size 0.4 0.6 0.7 0.8
Sample size per arm (No drop out) 51 23 18 14
Sample size per arm (10 % drop out) 86 38 28 22
Sample size per arm (15 % drop out) 91 41 30 23
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standard deviations will be calculated and tabulated for
quantitative data using SAS (SAS Institute, Cary, North
Carolina). Project-specific frequencies and percentages
will be presented as a recruitment diagram according to
CONSORT guidelines.
Qualitative data analysis
Qualitative data will be analyzed using QSR NVivo 8
(Qualitative Solutions and Research, Pty Ltd, Victoria,
Australia), a software program for managing, coding,
analyzing, and retrieving qualitative data. Data will be
coded electronically in NVivo 8 and printed out by code,
reviewed for accuracy, and examined for links to other
codes. This “axial coding” [95] process will connect code
categories and identify relationships between codes
which are suggestive of themes. Furthermore, as part of
the ongoing analytic process, comparing and contrasting
themes within and across the two strata (“constant com-
parison method”) will detect similarities and differences
in the data [95]. Verbatim quotes will be selected to val-
idate researchers’ coding and interpretations. The Z test
and Student’s t test will be used for continuous variables
satisfying normality assumption, and Mann Whitney U
test and Kruskal-Wallis Test will be applied for variables
which cannot satisfy the normal assumption. All statis-
tical comparison tests will be at a 95 % significance level.
Safety monitoring
Study procedures and participants will be monitored
throughout the course of the project to ensure patient
safety and minimal risk. Intervention and study coordi-
nators will monitor study participants at consent, all
data collection encounters, and during intervention
activities for any discomfort, satisfaction with study
participation, and for any questions or concerns par-
ticipants may have. At critical data collection junc-
tures, the PI will review the data set to ensure de-
identification prior to analysis. On a daily basis, the PI and
Biostatistician will ensure the security of all data files. The
National Institute of Arthritis And Musculoskeletal And
Skin Diseases (NIAMS)-appointed Safety Officer (SO),
Dr. Belmont, along with the Data and Safety Monitoring
Committee (DSMC), which will consist of Doctors Gary
Gilkeson, Holly Mitchell, and Diane Kamen, will review
safety and study conduct information on a semi-annual
basis or on an ad hoc basis should safety or privacy con-
cerns be raised. NIAMS determines the frequency of
safety reports that are submitted to the Safety Officer.
The frequency is most often bi-annually. The report
is submitted to KAI Research, Inc. (KAI) and KAI
will then inform NIAMS and the SO that it is avail-
able for their review.
Any adverse events (AE) or serious adverse events
(SAE) will be communicated to the USC IRB. AEs will be
collected during each follow-up phone call by prompting
participants to let the Intervention Coordinator and/or
GA know if they have experienced any AE. In addition,
should events be reported in-between follow-up calls,
those will be recorded immediately. The PI will be notified
of all AEs and SAEs. All SAEs will be reported to the inde-
pendent SO through KAI and NIAMS within 48 h of the
PI becoming aware of the event.
The study will only be stopped in the event of an un-
favorable safety review. Safety findings that might trigger
a safety review and would temporarily suspend enroll-
ment and/or study intervention until a safety review is
convened include the number of SAEs overall, the num-
ber of occurrences of a particular type of SAE, severe
AEs/reactions, or increased frequency of events. Such
findings will be presented to the study biostatistician or
to the DSMC to review the events by group to deter-
mine whether there are statistical as well as clinical con-
cerns. The statistician reports his findings to a closed
session of the DSMC or to the SO and/or NIA. The
findings are used to determine whether the study should
continue per protocol, proceed with caution, be further
investigated, be discontinued, or be modified and then
proceed.
Participants will always be given the option of discon-
tinuing participation in the event they are unhappy with
further participation. This is at the discretion of the par-
ticipant. Any participant assigned to the intervention or
set menu study arms during Year 1 who fails to
complete 3 or more of the 6 CDSMP/ASMP sessions
and/or fails to select and regularly participate in at least
one other intervention choice (listserv, support group,
mailed kit) for at least three consecutive months, will be
removed from their respective intervention arm and
coded/analyzed as a control participant since non-
participation will render them closer to the control or
usual standard of care arm. The study may be discontin-
ued at any time by the IRB, the NIA, the OHRP, the
FDA, or other government agencies as part of their du-
ties to ensure that research participants are protected.
A steering committee of seven mentors (JCO, KL,
SHG, DK, SB, SW, and ATM) will provide intensive
mentorship to the PI (EMW) and will be responsible for
the continued integrity of the intervention program and
its representation of USC and all affiliate organizations,
programs and institutions. Publication of the results of
this trial will be governed by the policies and procedures
developed by the Steering Committee. Any presentation,
abstract, or manuscript will be made available for review
by the sponsor and NIAMS prior to submission.
Discussion
Results from this trial will provide important insight into
the design and effectiveness of a culturally sensitive
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educational intervention which includes self-selection of
program components aiming to improve quality of life
and health status among African American patients with
lupus. We have built on three decades of empirical work
conducted in the field of arthritis self-management, but
differs in that the intervention mode, the disease (lupus),
and the study population (African Americans) are un-
studied or understudied. This psycho/educational inter-
vention is unique in that it will be a la carte. It will allow
each participant to choose which mode or modes by
which they care to participate. These modes include
small group, mail, and/or listserv discussion group. Such
a culturally sensitive educational intervention which
includes self-selection of program components has the
potential to improve disparate trends in quality of life,
disease activity and depression, and stress among African
American lupus patients, as better self-management out-
comes have been documented when participants are able
to choose/dictate the content and/or pace of the respect-
ive treatment/intervention program [68–71]. Since there
is currently no “gold standard” self-management program
specifically for SLE, the IQAN project may have a consid-
erable impact on future research and policy decisions.
Since this proposal addresses a health disparities need in
the field of lupus, wide-spread implementation in urban
communities that have large populations of underserved
minorities who would benefit from such an interventions
is an attainable goal.
Trial status
Currently, 153 participants have been randomized and
30 have completed all assessments.
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